



IN THE CLAIMS:

Please cancel claims 4, 5, 11-17, 28, 29, and 35-43.



4 ~~8~~ ^{TWICE} (Amended) A cyclodextrin copolymer of claim 1, wherein A is a protonated or non-protonated comonomer selected from the group consisting of: $\text{-HNC(O)(CH}_2\text{)}_x\text{C(O)NH-}$, $\text{-HNC(O)(CH}_2\text{)}_x\text{SS(CH}_2\text{)}_x\text{C(O)NH-}$, $\text{-}^+\text{H}_2\text{N(CH}_2\text{)}_x\text{SS(CH}_2\text{)}_x\text{NH}_2^+\text{-}$, $\text{-HNC(O)(CH}_2\text{CH}_2\text{O)}_x\text{CH}_2\text{CH}_2\text{C(O)NH-}$, $\text{-HNNHC(O)(CH}_2\text{CH}_2\text{O)}_x\text{CH}_2\text{CH}_2\text{C(O)NHNH-}$, $\text{-}^+\text{H}_2\text{NCH}_2(\text{CH}_2\text{CH}_2\text{O)}_x\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}_2^+\text{-}$, $\text{-HNC(O)(CH}_2\text{CH}_2\text{O)}_x\text{CH}_2\text{CH}_2\text{SS(CH}_2\text{CH}_2\text{O)}_x\text{CH}_2\text{CH}_2\text{C(O)NH-}$, $\text{-HNC(NH}_2^+\text{)(CH}_2\text{CH}_2\text{O)}_x\text{CH}_2\text{CH}_2\text{C(NH}_2^+\text{)NH-}$, $\text{-SCH}_2\text{CH}_2\text{NHC(NH}_2^+\text{)(CH}_2\text{)}_x\text{C(NH}_2^+\text{)NHCH}_2\text{CH}_2\text{S-}$, $\text{-SCH}_2\text{CH}_2\text{NHC(NH}_2^+\text{)(CH}_2\text{)}_x\text{SS(CH}_2\text{)}_x\text{C(NH}_2^+\text{)NHCH}_2\text{CH}_2\text{S-}$, $\text{-SCH}_2\text{CH}_2\text{NHC(NH}_2^+\text{)CH}_2\text{CH}_2(\text{OCH}_2\text{CH}_2\text{)}_x\text{C(NH}_2^+\text{)NHCH}_2\text{CH}_2\text{S-}$,



See
 11/6/01









B4
 cont'd



78

B


2/26
 11/6/01



4
 B
 cont'd

7/1

B








where $x = 1-50$, and $y+z=x$.


(Amended) A therapeutic composition comprising a cyclodextrin copolymer of claim 1, or 2, and a therapeutic agent.

(Amended) A method of claim 24, wherein A is a protonated or non-protonated comonomer

selected from the group consisting of: $\text{---HNC(O)(CH}_2)_x\text{C(O)NH---}$, $\text{---HNC(O)(CH}_2)_x\text{SS(CH}_2)_x\text{C(O)NH---}$, $\text{---}^+\text{H}_2\text{N(CH}_2)_x\text{SS(CH}_2)_x\text{NH}_2^+\text{---}$, $\text{---HNC(O)(CH}_2\text{CH}_2\text{O})_x\text{CH}_2\text{CH}_2\text{C(O)NH---}$, $\text{---HNNHC(O)(CH}_2\text{CH}_2\text{O})_x\text{CH}_2\text{CH}_2\text{C(O)NHNH---}$, $\text{---}^+\text{H}_2\text{NCH}_2(\text{CH}_2\text{CH}_2\text{O})_x\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}_2^+\text{---}$, $\text{---HNC(O)(CH}_2\text{CH}_2\text{O})_x\text{CH}_2\text{CH}_2\text{SS(CH}_2\text{CH}_2\text{O})_x\text{CH}_2\text{CH}_2\text{C(O)NH---}$, $\text{---HNC(NH}_2^+)(\text{CH}_2\text{CH}_2\text{O})_x\text{CH}_2\text{CH}_2\text{C(NH}_2^+)\text{NH---}$, $\text{---SCH}_2\text{CH}_2\text{NHC(NH}_2^+)(\text{CH}_2)_x\text{C(NH}_2^+)\text{NHCH}_2\text{CH}_2\text{S---}$, $\text{---SCH}_2\text{CH}_2\text{NHC(NH}_2^+)(\text{CH}_2)_x\text{SS(CH}_2)_x\text{C(NH}_2^+)\text{NHCH}_2\text{CH}_2\text{S---}$, $\text{---SCH}_2\text{CH}_2\text{NHC(NH}_2^+)\text{CH}_2\text{CH}_2(\text{OCH}_2\text{CH}_2)_x\text{C(NH}_2^+)\text{NHCH}_2\text{CH}_2\text{S---}$,







where $x = 1-50$, and $y+z=x$.

46. (Amended) A method of delivering a therapeutic agent comprising the steps of:
combining a cyclodextrin copolymer of claims 1, 8, 9, or 10, with a therapeutic agent to form a mixture; and
allowing said mixture to self-assemble to form an associated composition; and
administering a therapeutically effective amount of said associated composition to a subject in need of said therapeutic agent.

47. (New) A linear cyclodextrin copolymer comprising substituted or unsubstituted, cyclodextrin moieties bifunctionally bound in the linear copolymer backbone, through the number 2, 3, or 6 position of at least one glucopyranose ring of the cyclodextrin, to bifunctional moieties linking the cyclodextrins of the linear cyclodextrin polymer.

48. (New) A linear cyclodextrin copolymer of claim 1, 8, 9, 10, or 47 wherein said linear cyclodextrin copolymer is water soluble.

49. (New) A therapeutic composition comprising a cyclodextrin copolymer of claim 48 and a therapeutic agent.

50. (New) A method of treatment comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 48.

51. (New) A cyclodextrin copolymer of claim 48, wherein at least one ligand is bound to the linear cyclodextrin copolymer.

52. (New) A method of treatment comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 50.

52. (New) A therapeutic composition comprising a cyclodextrin copolymer of claim 47 and a therapeutic agent.

53. (New) A method of treatment comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 47.

54. (New) A cyclodextrin copolymer of claim 47, wherein at least one ligand is bound to the linear cyclodextrin copolymer.

55. (New) A method of treatment comprising the step of administering a therapeutically effective amount of a therapeutic composition of claim 54.

REMARKS

I. Status of the Claims

Claims 1-3, 6-10, 18, 24-27, 30-34, 44 and 46-55 are pending in this application. Claims 4, 5, 11-17, 28, 29, and 35-43 have been canceled. Applicants thank the Examiner for renumbering claim 47, added in Applicants' prior amendment, as claim 46. New claims 47-55 have been added. Support for new claims 47-55 can be found throughout the specification.

II. The Rejections Under 35 U.S.C. § 112

The Office Action, pages 3-14, contains two rejections under 35 U.S.C. § 112. Claims 1-18, 24-34, 37, 44 and 46 are rejected under 35 U.S.C. § 112, second paragraph, pages 3-12. Claims 1-18, 24-34, 37, 44, and 46 are also rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. Applicants have carefully considered the Examiner's remarks regarding these rejections. In view of those remarks and the Interview, Applicants have amended the claims to address points raised by the Examiner. Having cancelled claims 4, 5, 11-17, 28, 29, and 35-43 obviating many of the Examiner's specific remarks. With the pending claims in mind, Applicants provide the following remarks regarding the pending claims.

Applicants' claimed invention relates to linear cyclodextrin copolymers. Claim 1 and new claim 47 recite linear cyclodextrin copolymers. Claim 24 recites a method of preparing a linear cyclodextrin copolymer. That method copolymerizes a cyclodextrin monomer precursor, where

B